Founded in September 2019 by six partners including four CNRS researchers, the start-up created and supported by Erganeo, EverZom announces that it has obtained €2.5 million in European funding to accelerate the bioproduction of exosomes for the regenerative medicine of tomorrow.

With an R&D budget of €1.3 million for 2022, the biotech has three exclusive licenses on CNRS and University of Paris patents filed through SATT Erganeo. Its business model, which is expected to generate €500,000 next year, is based on its custom biomanufacturing services for research, which are marketed to some 20 biotechs and public laboratories, including France's Cellprothera and GoLiver , the UK's Mursla, Belgium's Novadip and Ireland's Omnispirant.

Learn more about EverZom

See the whole article